Novo Says Obesity Portfolio Led Growth, Wegovy Pill Uptake Continued in US
Novo said its obesity portfolio led growth, with continued US uptake of the Wegovy pill and encouraging early launches internationally.
Novo said its obesity portfolio led growth, with continued US uptake of the Wegovy pill and encouraging early launches internationally.